摘要
钾竞争性酸阻断剂(potassium-competitive acid blockers,P-CABs)是一类竞争性阻滞胃壁细胞质子泵上钾离子通道的药物,具有强效抑制胃酸分泌的功效,2019年在我国上市。代表药物有沃诺拉赞、瑞伐拉赞及特戈拉赞。目前主要用于胃食管反流病、消化性溃疡、幽门螺旋杆菌(H.pylori)根除以及上消化道出血的治疗和预防。本文就P-CABs作用机制、药代动力学特点、安全性及临床应用情况等方面进行当前研究进展的论述,旨在为新药临床应用及深入研究提供相应参考。
Potassium-competitive acid blockers(P-CABs)reversibly bind to proton pumps in a competitive manner with potassium ions,listed in China in 2019,it has a powerful effect of inhibiting gastric acid secretion.Representative drugs include Vonoprazan,Revaprazan and Tegoprazan.At present,it is mainly used for the treatment and prevention of gastroesophageal reflux disease,peptic ulcer,Helicobacter pylori(H.pylori)eradication and upper gastrointestinal bleeding.This article discussed the current research progress on the mechanism of action,pharmacokinetics,safety and clinical application of P-CABs,and aimed to provide corresponding references for new drug applications and in-depth research.
作者
买娟娟
韩莉
MAI Juanjuan;HAN Li(College of Traditional Chinese Medicine,Ji’nan University,Guangzhou 510632;Department of Digestive Disease,Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine;Department of Traditional Chinese Medcine,The First Affiliated Hospital of Jinan University,China)
出处
《胃肠病学和肝病学杂志》
CAS
2021年第5期589-592,共4页
Chinese Journal of Gastroenterology and Hepatology
关键词
钾竞争性酸阻断剂
沃诺拉赞
瑞伐拉赞
Potassium-competitive acid blockers
Vonoprazan
Revaprazan